Treatment of mental disorders, using Luvox

Luvox is an antidepressant for treatment of major depression associated with mood disorders.

Application

Depression of various origins, obsessive-compulsive disorder.

Contraindications: Hypersensitivity, hepatic failure, concomitant use of astemizole, cisapride, terfenadine, agents that inhibit MAO (including furazolidone, procarbazine, selegiline), breastfeeding, children under 8 years.

Restrictions apply to: Epilepsy, pregnancy; drug dependence, mania, hypomania, convulsive conditions or myocardial infarction.

Luvox Drug

Luvox Drug

Side effects

Of the 1087 patients, 22% of patients discontinued the drug because of side effects developed,. Among them were observed (in brackets the percentage of occurrence in the placebo group):

From the nervous system and sensory organs: headache 3% (1%), dizziness 2% (less than 1%), asthenia 2% (less than 1%), insomnia 4% (1%), somnolence 4% (less than 1% ), nervousness 2% (less than 1%), anxiety, 1% (less than 1%), 2% agitation (less than 1%).

From the gastrointestinal tract: nausea 9% (1%), anorexia 1% (less than 1%), dry mouth, 1% (less than 1%) Dyspepsia 1% (less than 1%), vomiting 2% (less than 1%), diarrhea 1% (less than 1%), abdominal pain 1% (0%).

In the placebo-controlled trials in patients with a frequency greater than 1% were observed following side effects:

From the nervous system and sensory organs: headache 22% (20%), dizziness 11% (6%), asthenia 14% (6%), drowsiness, 22% (8%), insomnia, 21% (10%), nervousness 12% (5%), anxiety 5% (3%), agitation of 2% (1%), depression, 2% (1%), CNS stimulation of 2% (1%), tremor 5% (1%), taste alteration 3% (1%), amblyopia 3% (2%).

Cardio-vascular system and blood (blood, hemostasis): palpitations 3% (2%), vasodilatation 3% (1%), hypertension 2% (1%).

The respiratory system: upper respiratory tract infections 9% (5%), dyspnea, 2% (1%), yawning 2% (0%).

From the digestive tract: anorexia 6% (2%), dry mouth, 14% (10%), damage to teeth 3% (1%), dysphagia 2% (1%), dyspepsia 10% (5%), nausea 40 % (14%), flatulence 4% (3%), diarrhea 11% (7%) constipation 10% (8%), 5% vomiting (2%).

With the genitourinary system: abnormal ejaculation 8% (1%), decreased libido 2% (1%), impotence 2% (1%), anorgasmia 2% (0%), frequent urination 3% (2%), urinary retention 10%).

Other: flu-like symptoms 3% (2%), chills 2% (1%), sweating 7% (3%).

Symptoms

Dizziness, drowsiness, dry mouth, nausea, vomiting, diarrhea, or bradi- tachycardia, hypotension, ECG changes, abnormal liver function, mydriasis, tremor, myoclonus, seizures, oliguria, coma. Described deaths.

Treatment

Stimulation of vomiting or gastric lavage, activated charcoal, ECG monitoring, maintenance of vital functions, symptomatic therapy. There is no specific antidote. Dialysis and diuresis are inefficient.

Dosage and administration: Inside, adults, not liquid, squeezed small amounts of water. Initial dose: 50-100 mg / day one (night). With good endurance: increase the dose to 150-200 mg / day in 2-3 divided doses. The maximum daily dose is 300 mg.